Status:
COMPLETED
Vitamin D Deficiency in Adolescent Girls
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Healthy
Vitamin D Deficiency
Eligibility:
FEMALE
9-18 years
Phase:
NA
Brief Summary
Fibroblast growth factor 23 (FGF23) is a newly discovered hormone which regulates phosphate and vitamin D levels. In this study, we are looking at what the normal levels of FGF23 are in adolescent gir...
Detailed Description
Fibroblast growth factor 23 (FGF23) is a newly discovered hormone. Its primary function is to regulate phosphate metabolism, which it does both by directly regulating phosphate excretion through the k...
Eligibility Criteria
Inclusion
- healthy girls aged 9-18 years
Exclusion
- significant cardiac, hepatic, oncologic, or psychiatric disease
- a history of malabsorption, kidney stones, hypoparathyroidism, or growth hormone deficiency
- pregnancy
- diabetes mellitus
- BMI\>/= 99th percentile for age and sex
- fracture within the preceding 3 months
- hypogonadism (no pubertal development by age 12, absence of menarche by age 14)
- serum calcium \<8 mg/dl or \>11 mg/dl
- radiographic evidence of rickets
- use of medications know to affect serum phosphate levels including phosphate-binding antacids, sodium etidronate, calcitonin, excessive doses of vitamin D (\>1000 units per day), excessive doses of vitamin D (\>20,000 units/day), calcitriol, growth hormone, or anti-convulsants.
- use of hormonal birth control
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT01180946
Start Date
September 1 2010
End Date
April 1 2013
Last Update
November 5 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114